ACP
EPIX

Acuta Capital Partners’s ESSA Pharma EPIX Stock Holding History

Acuta Capital Partners’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-232,896
Closed -$6.65M – 53
2021
Q2 		$6.65M Sell
232,896
-54,104
-19% -$1.57M 2.66% 12
2021
Q1 		$8.34M Buy
+287,000
New +$6.67M 3.01% 11
2017
Q3 		– Sell
-22,100
Closed -$242K – 69
2017
Q2 		$242K Sell
22,100
-8,165
-27% -$267K 0.07% 56
2017
Q1 		$1.88M Hold
30,265
– – 0.44% 40
2016
Q4 		$1.33M Buy
30,265
+930
+3% +$40.5K 0.49% 32
2016
Q3 		$1.68M Buy
29,335
+823
+3% +$44K 0.63% 39
2016
Q2 		$1.75M Buy
28,512
+5,145
+22% +$321K 0.84% 34
2016
Q1 		$1.52M Buy
23,367
+7,242
+45% +$472K 0.85% 28
2015
Q4 		$1.48M Buy
16,125
+1,705
+12% +$178K 0.71% 35
2015
Q3 		$1.8M Buy
+14,420
New +$2.01M 1.04% 34

Other funds holding EPIX

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Acuta Capital Partners's EPIX Position: Q3 2021 in Review

Acuta Capital Partners sold out of ESSA Pharma (EPIX) in Q3 2021, closing a stake of 232,896 shares — an estimated $6.65M sold.

Acuta Capital Partners first reported a position in EPIX in Q3 2015 and held it in 10 quarters. The position peaked at $8.34M in Q1 2021. 75 funds tracked by Wall St. Rank hold EPIX as of Q3 2021.

  • Acuta Capital Partners reported no remaining ESSA Pharma position as of Q3 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 232,896 ESSA Pharma shares in Q3 2021, an estimated $6.65M.
  • Acuta Capital Partners first reported a position in ESSA Pharma in Q3 2015 and held it in 10 quarters.
  • Acuta Capital Partners's ESSA Pharma position peaked at $8.34M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held ESSA Pharma as of Q3 2021.

Based on Acuta Capital Partners's 13F filing for Q3 2021, filed 15 Nov 2021.